DEspRhigh neutrophils are associated with critical illness in COVID-19

被引:0
作者
Joanne T. deKay
Ivette F. Emery
Jonathan Rud
Ashley Eldridge
Christine Lord
David J. Gagnon
Teresa L. May
Victoria L. M. Herrera
Nelson Ruiz-Opazo
Richard R. Riker
Douglas B. Sawyer
Sergey Ryzhov
David B. Seder
机构
[1] Maine Medical Center Research Institute,Department of Critical Care Services
[2] Maine Medical Center,Whitaker Cardiovascular Institute and Department of Medicine
[3] Boston University School of Medicine,undefined
[4] Tufts University School of Medicine,undefined
来源
Scientific Reports | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
SARS-CoV-2 infection results in a spectrum of outcomes from no symptoms to widely varying degrees of illness to death. A better understanding of the immune response to SARS-CoV-2 infection and subsequent, often excessive, inflammation may inform treatment decisions and reveal opportunities for therapy. We studied immune cell subpopulations and their associations with clinical parameters in a cohort of 26 patients with COVID-19. Following informed consent, we collected blood samples from hospitalized patients with COVID-19 within 72 h of admission. Flow cytometry was used to analyze white blood cell subpopulations. Plasma levels of cytokines and chemokines were measured using ELISA. Neutrophils undergoing neutrophil extracellular traps (NET) formation were evaluated in blood smears. We examined the immunophenotype of patients with COVID-19 in comparison to that of SARS-CoV-2 negative controls. A novel subset of pro-inflammatory neutrophils expressing a high level of dual endothelin-1 and VEGF signal peptide-activated receptor (DEspR) at the cell surface was found to be associated with elevated circulating CCL23, increased NETosis, and critical-severity COVID-19 illness. The potential to target this subpopulation of neutrophils to reduce secondary tissue damage caused by SARS-CoV-2 infection warrants further investigation.
引用
收藏
相关论文
共 751 条
  • [1] Yazdanpanah F(2020)The immune system and COVID-19: Friend or foe? Life Sci. 256 117900-117900
  • [2] Hamblin MR(2020)Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2 Signal Transduct Target Ther. 5 84-17
  • [3] Rezaei N(2021)Immunopathology of hyperinflammation in COVID-19 Am. J. Pathol. 191 4-e261
  • [4] Catanzaro M(2021)Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: A cohort study Lancet Rheumatol. 3 e253-704
  • [5] Fagiani F(2021)Dexamethasone in hospitalized patients with Covid-19 N. Engl. J. Med. 384 693-631226
  • [6] Racchi M(2021)Inflammation and antiviral immune response associated with severe progression of COVID-19 Front. Immunol. 12 631226-1659
  • [7] Corsini E(2021)COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation Mediat. Inflamm. 2021 8874339-107233
  • [8] Govoni S(2020)The beneficial and pathogenic roles of complement in COVID-19 Cleve Clin. J. Med. 51 1652-1440
  • [9] Lanni C(2021)Complement cascade in severe forms of COVID-19: Recent advances in therapy Eur. J. Immunol. 2021 107233-329
  • [10] Gustine JN(2021)Neutrophils and COVID-19: The road so far Int. Immunopharmacol. 18 206-872